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RESUMO
Implante Transcateter de Bioprótese Valvular 
Pulmonar: Revisão Sistemática da Literatura
A correção cirúrgica de algumas cardiopatias congênitas com-
plexas envolve a reconstrução da via de saída do ventrículo 
direito com a interposição de homoenxertos, biopróteses, 
enxertos de jugular bovina ou outros condutos valvulados 
entre o ventrículo direito e o tronco da artéria pulmonar. 
Apesar de essas cirurgias poderem ser realizadas com bai-
xa mortalidade, a vida útil das válvulas ou dos condutos 
implantados é normalmente pequena (< 10 anos), seja por 
degeneração e/ou calcificação. Graus variáveis de estenose 
pulmonar na maioria das vezes associada à insuficiência 
pulmonar são consequências da degeneração dos condutos. 
Em 2000, Bonhoeffer et al. foram os primeiros a relatar o 
implante transcateter de bioprótese valvular pulmonar (ITVP) 
com um dispositivo que posteriormente foi denominado de 
válvula Melody (Medtronic – Minneapolis, Estados Unidos). 
A técnica foi inicialmente desenvolvida para limitar a neces-
sidade de múltiplos procedimentos cirúrgicos, substituindo, 
em última análise, uma nova troca cirúrgica valvular. Estudos 
subsequentes na Europa e Estados Unidos atestaram para a 
ABSTRACT
Surgical repair of some complex congenital heart diseases 
involves reconstruction of the right ventricular outflow tract 
using homografts, bioprostheses, bovine jugular grafts or other 
valved conduits between the right ventricle and the main 
pulmonary artery. Although these surgical procedures may 
be performed with low mortality rates, the life span of these 
implanted valves or conduits is usually short (< 10 years) due 
to either degeneration and/or calcification. Variable degrees 
of pulmonary stenosis, often associated with pulmonary insuf-
ficiency, are consequences of conduit degeneration. In 2000, 
Bonhoeffer et al. were the first to report the transcatheter pul-
monary valve implantation (TPVI) of a bioprosthetic pulmonary 
valve later named Melody valve (Medtronic, Minneapolis, 
USA). The technique was initially developed to limit the need 
for multiple surgical procedures, and, ultimately, to work as 
a surrogate of a new surgical valve replacement. Subsequent 
clinical studies in Europe and the United States confirmed 
the safety and efficacy of this technique in a larger number 
of patients. Since the National Sanitary Surveillance Agency 
(Agência Nacional de Vigilância Sanitária – Anvisa) granted 
approval for clinical use of the Melody transcatheter pulmonary 
biological valve in February 2103, we deemed that a judicious 
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S urgical correction of some complex and less frequent congenital heart diseases involves reconstruction of the right ventricular (RV) outflow tract with the 
interposition of homografts, bovine jugular bioprosthe-
ses grafts, or other valved conduits between the right 
ventricle and the main pulmonary artery. Examples of 
diseases that may require such strategy include tetral-
ogy of Fallot, pulmonary atresia with ventricular septal 
defect, double-outlet right ventricle with infundibular 
pulmonary stenosis, transposition of the great arteries 
with ventricular septal defect and infundibular pulmonary 
stenosis, and persistent truncus arteriosus. Ross procedure, 
used for reconstruction of the left ventricular outflow 
tract in case of double aortic lesion, also involves this 
strategy. Although these reconstructive surgeries of the 
right outflow tract ventricle can be performed with 
low mortality,1 the duration of the implanted valves 
or conduits is usually small (< ten years), due to de-
generation and/or calcification of the materials used 
for their manufacture. Varying degrees of pulmonary 
stenosis, most often associated to pulmonary failure, 
are the result of conduit degeneration. The earlier the 
interposition is performed; the lower is the durability 
of the conduit. Such observation results in the need 
to perform several open-heartsurgeries,1 which have 
great impact on patients’ health and quality of life, 
especially in the case of children. In addition, a new 
pulmonary valve replacement surgical requires the use 
of cardiopulmonary bypass (CPB), which can worsen 
the RV function, usually already compromised.2,3
By mid-2000,4 the therapeutic alternatives to a new 
surgical valve replacement were limited. The percutane-
ous implantation of bare-metal stents in these stenotic 
conduits or bioprostheses was used both in Brazil and 
abroad,5,6 aiming to increase survival and minimize the 
need for repeated invasive procedures. Despite provid-
ing the possibility of postponing a new surgery, this 
strategy results in total pulmonary failure with currently 
well known deleterious effects, including arrhythmias, 
ventricular dysfunction, and decreased aerobic capacity. 
In 2000, Bonhoeffer et al.7 were the first to report the 
transcatheter pulmonary biological valve implantation, 
later named the Melody valve (Medtronic, Minneapolis, 
USA). This valve is made with bovine jugular vein tissue 
and mounted on a stent.7,8 The technique was origi-
nally developed to limit the need for multiple surgical 
procedures, ultimately replacing a new surgical valve 
exchange.1 Subsequent studies confirmed the safety and 
efficacy of this technique,4,8 which has been used in 
over 1,000 patients in the world, especially in Europe.9
As it occur with the less prevalent diseases, to date 
there have been no prospective, randomized trials with 
a large number of patients to definitively guide the 
treatment of dysfunction in these conduits in the RV 
outflow tract. This is due to the difficulty in performing 
controlled and randomized clinical trials for a small 
population of patients with rare diseases. In addition, 
there are ethical issues that make it impossible to 
compare a less invasive procedure with more invasive 
surgical treatments. The Food and Drug Administration 
(FDA) has adapted to these particularities in treatment 
research for uncommon diseases. A review of the recent 
approvals demonstrates that some drugs were approved 
based on phase II studies and even in a historical series 
of cases. In the case of the transcatheter pulmonary valve 
Melody, the FDA granted humanitarian approval to the 
device between late 2009 and early 2010, based on 
a study of a large case series performed in five ameri-
cans centers of excellence. The Humanitarian Device 
Exemption (HDE) program was established in 1990, 
aiming to create an alternative path to accelerate the 
introduction in the market of technologies directed to 
the treatment of patients with rare diseases or conditions. 
According to FDA rules, when a device is intended 
to benefit patients with a disease or a condition that 
affects fewer than 4,000 individuals per year, there is 
an incentive from the U.S. government, which by a 
federal law offers the manufacturer exemption from the 
segurança e eficácia dessa técnica em um número maior de 
pacientes. Como a Agência Nacional de Vigilância Sanitária 
(Anvisa) concedeu a aprovação para o uso clínico da válvula 
biológica pulmonar transcateter Melody em fevereiro de 2013, 
consideramos necessária e oportuna a avaliação judiciosa da 
utilização dessa nova tecnologia antes que ela fosse aplicada 
em larga escala em nosso país. O objetivo deste estudo foi 
realizar uma revisão sistemática da literatura sobre o ITVP 
em pacientes com disfunções de homoenxertos, condutos 
valvulados e biopróteses implantados cirurgicamente na via 
de saída do ventrículo direito.
DESCRITORES: Valva pulmonar. Cateterismo cardíaco. Próteses 
valvulares cardíacas. Próteses e implantes. Revisão.
assessment of this new technology was timely and necessary 
before the widespread use in our country. The objective of 
this study was to perform a systematic literature review on the 
use of TPVI in patients with dysfunctional homografts, valved 
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requirements of efficiency and effectiveness. However, it 
is necessary to demonstrate to the FDA that the device 
is safe for patients and that the benefits outweigh the 
risks. In addition, the applicant must demonstrate that 
there is no comparable device available for treatment 
or diagnosis of the same disease or condition. The goal 
of the humanitarian approval is to benefit a popula-
tion that would not be treated if the requirements for 
approval of these devices for diseases and rare condi-
tions were the same as for other devices. Moreover, 
this initiative encourages companies that manufacture 
medical devices to develop technologies that meet 
these populations’ needs.
Evidence-based medicine uses techniques and 
tools that assist in the search and synthesis of the best 
available information in the literature. Currently, these 
techniques are being increasingly used for creating pro-
tocols and guidelines throughout the world, including 
Brazil. Since the Brazilian Health Surveillance Agency 
(Agência Nacional de Vigilância Sanitária – ANVISA) 
granted approval for clinical use of the Melody trans-
catheter pulmonary biological valve in February 2103, 
a judicious assessment of this new technology was 
deemed timely and necessary before its widespread 
use in Brazil (Appendix).
OBJECTIVE
This study aimed to perform a systematic review 
the literature on the use of bioprosthesis transcatheter 
pulmonary valve implantation (TPVI) in patients with 
dysfunctional homografts, valved conduits, and surgically-
implanted bioprostheses in the RV outflow tract.
METHODS
Literature review and an extensive search in the 
computerized databases EMBASE, LILACS, and MED-
LINE were performed, using the words “transcatheter 
pulmonary valve” and “treatment”.
The combination of these terms provided the set 
of references considered for analysis. The search was 
restricted to articles in human subjects and of the fol-
lowing types: randomized controlled trials, systematic 
reviews or narratives, meta-analysis, guidelines, clinical 
studies, and case series. The search was not restricted 
regarding date or language.
Articles resulting from the analysis were reviewed, 
as well as the references of the current guidelines. No 
meta-analysis of the obtained data was performed. 
In the Cochrane Library, the term “transcatheter 
pulmonary valve” was used to search for systematic 
reviews.
A search was also performed in annals of con-
gresses of medical specialty societies, such as the 
Brazilian Society of Hemodynamics and Interventional 
Cardiology (Sociedade Brasileira de Hemodinâmica e 
Cardiologia Intervencionista – SBHCI) and the Brazil-
ian Society of Cardiology (Sociedade Brasileira de 
Cardiologia – SBC).
The first two authors of this manuscript per-
formed the literature review and initial drafting of 
the manuscript; both work for Evidências company. 
Subsequently, the article was critically reviewed 
by interventionists, specialized in congenital heart 
disease, who are familiar with the subject and will 
soon be involved in this type of procedure in Brazil. 
All interventionists are associated in some way to 
SBHCI, which supported this initiative.
Studied intervention
The intervention assessed in this review was the TPVI.
Description of the studied device for 
bioprosthesis transcatheter pulmonary valve 
implantation
There are two types of prosthesis used in TPVI. The 
oldest is called the Melody valve, the only prosthesis 
approved in Brazil for use in the pulmonary position. 
Since almost all of the evidence found in the literature is 
based on the use of this device, this review will address 
mainly this type of prosthesis. The second prosthesis 
is the SAPIEN valve (Edwards, Irvine, United States), 
approved in Brazil for use in the aortic position only, 
although the valve itself is practically the same.
There are two components in the Melody valve 
system: the Melody transcatheter pulmonary valve itself, 
model PB10 (bovine jugular valve with stent) (Figure 1) 
and the Ensemble transcatheter valve delivery system 
Figure 1 – External aspect of the Melody valve. The bovine jugular 
is mounted inside the CP (cheatham-platinum) stent. (Photos courtesy 
of Medtronic).
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(Medtronic, Minneapolis, United States), NU10 model 
(Figures 2 and 3).
The Melody transcatheter pulmonary valve is com-
posed by a heterologous (bovine) jugular valve sutured 
within a platinum-iridium laser-welded stent, and the 
stent has gold-welded joints. The system is submitted to 
a final sterilisation procedure with an adequate sterilising 
agent containing 1% glutaraldehyde and 20% isopropyl 
alcohol, in which the valve and stent are preserved and 
packed until they are used.
The Ensemble transcatheter valve delivery system 
consists of a balloon-in-balloon catheter with a polytet-
rafluoroethylene retractable sheath and a distal support 
that is large enough to frontally carry the valve, after 
the valve with the stent has been compressed and 
adapted to the balloon. The delivery system is available 
in sizes of 18 mm, 20 mm, and 22 mm. The sheath of 
the catheter has a side port used to flush the system 
and a hemostatic sleeve on the sheath to minimize 
bleeding at insertion. The catheter has a conical distal 
obturator made of polyether-b-amide (Pebax; Arkema 
– Colombes, France). The delivery system is compatible 
with a guide wire of 0.889 mm.
Patients involved
Patients were both children and adults with objective 
dysfunctions (severe stenosis and/or severe insufficiencies) 
in homografts, valved conduits, and bioprostheses surgi-
cally implanted in the RV outflow tract.
Analysis of the results obtained in the study 
search 
All references retrieved through the search strategies 
had their title and abstracts read by two researchers, the 
first authors of this article. If there was any indication 
that a reference could meet the inclusion criteria of this 
study, it was included in a list of selected studies. The 
corresponding original article was obtained for every 
selected reference. Each of those articles was read by 
the researchers, who assessed whether they met the 
inclusion criteria.
All articles that met the inclusion criteria were 
separated for data extraction.
Data Extraction
A careful analysis and reading was performed for 
each article included, in order to extract data.
A specific form for data extraction was prepared. 
The data from each included study were extracted 
independently by two reviewers. The name of the first 
author and year of publication were used to identify 
the study. All data were extracted directly from the 
published articles.
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The following variables were assessed:
 • characteristics of patients;
 • characteristics of the procedure performed;
 • hemodynamic results after TPVI; and
 • safety data.
RESULTS
Figure 4 presents the flow chart used for identi-
fication of the included studies, as recommended by 
the Preferred Reporting Items for Systematic reviews 
and Meta-analysis (PRISMA).10 A total of 132 studies 
were obtained in the first search, whose articles on 
other (non-pulmonary) heart valves were not used for 
preparation of this systematic review. Additionally, 
animal studies and studies without a description of 
clinical or laboratory outcomes were excluded. Of 
this total, 15 studies met the inclusion criteria for this 
analysis. 
Characteristics of patients and identified  
studies
Most studies included patients with RV outflow tract 
disorders (stenosis, pulmonary insufficiency, or mixed 
disorders), after one or more repairs for congenital 
heart disease with New York Heart Association (NYHA) 
functional class > II.
No randomized studies or systematic reviews were 
retrieved on the subject. The published studies are 
mostly case reports or retrospective studies.
In all studies, the procedure was performed un-
der general anaesthesia, after the patient had been 
heparinized and received prophylactic antibiotics. 
The access route was reported in six studies;4,8,11-14 
the femoral vein was most often chosen, followed by 
the jugular vein.
Age varied between studies, but most patients who 
underwent the implantation were young adults (Table 
1). The Melody valve was predominantly implanted 
in the published studies (94 %), with a success rate 
> 90%. Only one study used the SAPIEN valve.15 
The mean time of procedure was 140 minutes (Table 
1). Patients were discharged approximately two days 
after the procedure.11,16 The main indications for the 
procedure were:
• significant pulmonary insufficiency and/or pul-
monary stenosis;
 • RV dilation;
 • RV dysfunction;
Figure 4 – Flow chart forstudy identification.
Figure 3 – Melody valve mounted on the balloon (partially inflated) 
in the Ensemble system.
Excluded studies (n = 110)
– Other diseases (or other heart
   valves)
– Animal studies
– No clinical outcomes described
Excluded studies (n = 7)
– Other diseases (or other heart
   valves)
Potentially relevant studies
identified (n = 132)
Studies selected
and retrieved for full text analysis
(n = 22)
Total studies included (n = 15)
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 • reduction in exercise tolerance; and
 • diameter of the original conduit at the RV outflow 
tract > 16 mm and/or < 22  mm.
Patients with the following characteristics were 
excluded from the procedure:
 • known heparin and acetylsalicylic acid allergies;
 • pregnancy;
 • active endocarditis;
 • clinical or biological signs of infection; and
 • obstruction of the central veins.
Description of the studies
Khambadkone, 2005 (level of evidence 4C)
The first study retrieved was published in2005 by 
Khambadkone et al.8 This study reported the data of 
59 patients previously submitted to surgery at the RV 
outflow tract due to congenital heart disease, with signs 
of dysfunction of outlet right ventricle and intervention 
indications such as RV hypertension (more than two-thirds 
of systemic blood pressure) with pulmonary stenosis or 
pulmonary insufficiency, RV dilation or failure. Most 
patients (58/59) were successfully submitted to TPVI via 
femoral artery (Table 2). Echocardiography performed 
24 hours after the TPVI confirmed the immediate 
hemodynamic findings, showing gradient decrease in 
the RV outflow tract (63.4 ± 23.4 to 40.5 mmHg ± 
18.2 mmHg; P < 0.001). The number of patients with 
pulmonary insufficiency > grade II also decreased sig-
nificantly after the procedure (P < 0.001).5 There was 
improvement in NYHA functional class I to II (P < 0.001). 
Nuclear magnetic resonance imaging (NMRI) performed 
in 28 cases showed significant reduction in the pulmo-
nary regurgitation fraction, from 21 ± 13% to 3 ± 4% 
(P < 0.001) and in RV end-diastolic volume from 94 
± 28 mL to 82 ± 24 mL × beat-1 xm-2 (P < 0.001).The 
rate of complications was small (Table 3).
TABLE 1  
Characteristics of included studies
Study
Age, in years 





Level of evidence 
(degree of 
recommendation)
Khambadkone et al. 
(2005)8 
16 (9-43) Medtronic Melody Femoral (57) 
Jugular (2)
102 min 9.8 months 4C
Coats et al. (2006)17 20 (9-51) Medtronic Melody NR 77.6 min NR 4C
Coats et al. (2007)18 21,2 (± 8,7) Medtronic Melody NR NR NR 4C
Lurz et al. (2008)4 21,2 (7-71) Medtronic Melody Femoral (148) 
Jugular (7)
NR 28.4 months 4C
Momenah et al. 
(2009)12 
14,3 (10-23) Medtronic Melody Femoral (13) 102 min 4 months 4C
Zahn et al. (2009)19 19,4 (± 7,7) Medtronic Melody NR 182 min 6 months 3 B
Nordmeyer et al. 
(2009)20 
28 (± 5) Medtronic Melody NR 99 min 12 months 4C
Martins et al. (2010)9 19 (9-35) Medtronic Melody NR 180 min 7.8 months 4C
Asoh et al. (2010)11 15,4 (13-19) Medtronic Melody Femoral (11)
Jugular (3)
NR 12.9 months 4C
Vezmar et al. (2010)13 14,9 (10,9-19) Medtronic Melody Femoral (23)
Jugular (5)
150 min 27.6 months 4C
Kenny et al. (2011)15 30,3 (± 15,1) Edwards SAPIEN NR 144 min 6 months 4C
Eicken et al. (2011)16 21,5 (16,2-30) Medtronic Melody NR NR 12 months 4C
Biernacka et al. (2011)21 23,4 (± 5,6) Medtronic Melody NR NR 12 months 4C
Butera et al. (2013)14 24 (11-65) Medtronic Melody Femoral (59)
Jugular (4)
170 min 30 months 3B
Gillespie et al. (2013)22 NR Medtronic Melody NR NR 12 months 4C
NR, Not Reported or not found 
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TABLE 2  
Immediate hemodynamics results after transcatheter pulmonary valve bioprosthesis implantation
Study n
Right ventricular  
systolic pressure
Right ventricular  
outflow tract gradient
Pulmonary artery  
systolic pressure
Pulmonary artery  
diastolic pressure
Pre Post P Pre Post P Pre Post P Pre Post P
Khambadkone et al.
(2005)8
59 64,4 ± 17 50,4 ± 14 <0,001 33 ± 24,6 19,5 ± 15 <0,001 NR NR NR 9,9 ± 3,7 13,5 ± 5,3 <0,001
Coats et al.  
(2006)17
18 72.8 ± 18 47.3 ± 9.6 <0.001 51,4 ± 21 21.7 ± 8.9 <0.001 21.4 ± 6.2 25.7 ± 8.5 0.004 10.8 ± 3.6 11.9 ± 8.6 0,16
Coats et al.  
(2007)18
17 51.3 ± 13 42 ± 9.7 0.003 20 ± 14 14 ± 8.5 0.042 31.3 ± 8.9 28 ± 8.1 0.253 8.9 ± 4.5 12.5 ± 5.2 0.041
Lurz et al.  
(2008)4
155 63 ± 18 45 ± 13 <0.001 37 ± 20 17 ± 10 <0.001 27 ± 11 29 ± 12 0.056 10 ± 4 14 ± 9 <0.001
Momenah et al. 
(2009)12
13 61.2 ± 14 37.6 ± 6.7 <0.05 39.6 ± 15 12.1 ± 9 <0.05 NR NR NR 8.1 ± 2.6 11.5 ± 2.8 <0.05
Zahn et al.  
(2009)19
30 67.7 ± 16 48.9 ± 13.7 <0.001 37.2 ± 16 17.3 ± 7.3 <0.001 NR NR NR 11 ± 5.2 14.7 ± 5.1 <0.001
Nordmeyer et al. 
(2009)20
12 NR NR NR 34 ± 6 14 ± 3 <0.01 NR NR NR NR NR NR
Martins et al.  
(2010)9
7 94 ± 27 44 ± 7 NR 65 ± 28 11 ± 4 NR NR NR NR 10 ± 1 14 ± 2 NR
Asoh et al.  
(2010)11
14 62.2 ± 21 42.4 ± 11 <0.005 36.7 ± 19 12.9 ± 7.3 <0.05 NR NR NR NR NR NR
Vezmar et al. 
(2010)13
28 61 ± 16 41 ± 11 <0.001 36 ± 15 12 ± 7 <0.001 26 ± 8 30 ± 9 0.02 11 ± 4 15 ± 5 0.003
Kenny et al.  
(2011)15
34 55.3 ± 18 42 ± 13 <0.001 26.8 ± 18 11.7 ± 8 <0.001 NR NR NR 9.3 ± 3.1 12.4 ± 5.5 <0.001
Eicken et al.  
(2011)16




<0.001 NR NR NR NR NR NR
Biernacka et al. 
(2011)21
22 NR NR NR 85 ± 39 35.6 ± 13 <0.001 NR NR NR NR NR NR
Butera et al.  
(2013)14
63 80 20 ± 10 <0.001 45 10 <0.001 NR NR NR NR NR NR
Gillespie et al. 
(2013)22
104 71.6 ± 21 46.7 ± 15 <0.001 38.7 ± 16 10.9 ± 6.7 <0.001 NR NR NR NR NR NR
NR, Not Reported or not found 
Coats, 2007 (level of evidence 4C)
In 2006, Coats et al.17 reported the results of 18 
patients with pure isolated pulmonary stenosis in 93 
patients undergoing TPVI. The results also were favorable 
to the procedure. There was a significant improvement 
in NYHA functional class I to II (P < 0.001) one month 
after the procedure. The echocardiography revealed a 
significant decrease in RV systolic pressure (from 84.9 
± 17.5 mmHg to 50.7 ± 14.4 mmHg; P < 0.001) and 
in the RV outflow tract gradient (85.2 ± 19 mmHg to 
41.1 ± 12.3 mmHg; P < 0.001). In the following year, 
the same authors published data on 17 patients with 
pure isolated pulmonary insufficiency undergoingTPVI.18 
The results were also favorable to the procedure, with 
significant improvement in NYHA functional class from 
II to I (P < 0.001). The improvement in hemodynamics 
was more significant in patients with pure pulmonary 
insufficiency, when compared to those with pulmonary 
insufficiency, and is described in Table 2.
Lurz 2008 (level of evidence 4C)
The largest case series was published in 2008 by 
Lurz et al.,4 with 155 patients, and included patients 
who underwent the procedure at the initial phase of 
the learning curve. Most patients had NYHA functional 
class > II. Among the patients, 61 had predominantly 
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pulmonary stenosis, 46 had pulmonary insufficiency, 
and 44 had combined dysfunctions. Hemodynamic 
benefits are described in Table 2. The absence of 
reintervention in70 months was 70%. In this group, 
most reinterventions were performed due to valved 
stent fractures, which is why the preparation of the 
conduit with previous implantation of a conventional 
stent (non-valved) in conduit (pre-stenting) was later 
included in the technique. Another risk factor for 
reintervention was the finding of immediate residual 
gradients > 25 mmHg, indicating the need to elimi-
nate gradients through the technique of preparing the 
conduit with bare-metal stents. The learning curve 
also played an important role in reducing the need 
for new procedures, with significant improvement 
in latest two-thirds of the treated cohort. In 2009, 
three more studies12,19,20 were published, with positive 
hemodynamic results for TPVI.
Zahn, 2009 (level of evidence 3B)
Zahn et al.19 reported data on 30 patients with 
a success rate of the procedure in 29 Melody valve 
implantations. During the study follow-up, 100% of the 
patients were free of new procedures, and 79% of the 
24 patients with NYHA functional class ≥ II showed 
functional class improvement. This study was continued, 
and culminated in another study that resulted in the 
approval of the Melody prosthesis by the FDA under 
the afore mentioned HDE provision.
Nordmeyer, 2009 (level of evidence 4C)
Nordmeyer et al.20 published the results of12 patients 
undergoing TPVI, of whom 50% had predominantly 
pulmonary stenosis, 33% had pulmonary insufficiency, 
and 17% had mixed dysfunctions. The success rate of 
the procedure was 100 %, and no acute complications 
were related to the procedure.
Momenah, 2009 (level of evidence 4C)
In the study by Momenah et al.,12 the procedure was 
performed in 13 patients with no acute or late procedure-
related complications. This study had a follow-up of only 
four months. The echocardiography performed 24 hours 
after the TPVI procedure showed reduction in RV systolic 
pressure and in the RV outflow tract gradient. Three other 
studies were published in 2010.9,11,13
Martins, 2010 (level of evidence 4C)
Martins et al.9 reported data on 13 patients submitted 
to TPVI. The predominant dysfunction in the RV outflow 
tract was the mixed lesion, and all patients underwent 
pre-stenting of the conduit. Angiographic results showed 
resolution of stenosis and/or insufficiency in all patients. 
There were no procedure-related complications.
Vezmar, 2010 (level of evidence 4C)
In the study by Vezmar et al.,13 17 patients (61%)had 
mixed lesions, nine (32%) had pure pulmonary stenosis, 
TABLE 3  
Rate of procedure-related complications during follow-up
Study n Stent fracture Arrhythmias Endocarditis Mortality
Khambadkone et al. (2005)8 59 12 NR 1 0
Coats et al. (2006)17 18 NR NR NR NR
Coats et al. (2007)18 17 NR NR NR NR
Lurz et al. (2008)4 155 32 2 5 4
Momenah et al. (2009)12 13 0 0 0 0
Zahn et al. (2009)19 30 1 1 NR 0
Nordmeyer et al. (2009)20 12 2 NR 1 0
Martins et al. (2010)9 7 NR NR NR 0
Asoh et al. (2010)11 14 0 NR NR 0
Vezmar et al. (2010)13 28 3 NR NR 0
Kenny et al. (2011)15 34 0 2 NR NR
Eicken et al. (2011)16 102 2 1 1 1
Biernacka et al. (2011)21 22 0 NR NR 0
Butera et al. (2013)14 63 2 1 2 3
Gillespie et al. (2013)22 104 2 NR 3 0
NR, Not Reported or not found 
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and two (7%) had isolated pulmonary insufficiency. The 
parameters of the echocardiography performed within 
the first 24 hours showed decreased RV pressure and 
RV outflow tract gradient. One month after the TPVI, 
80%of the patients had no detectable pulmonary insuf-
ficiency, 68% of whom had pulmonary insufficiency ≥ 
grade 3 before the procedure (P < 0.001).The time free 
from reintervention was 83% at 36months of follow-up.
Asoh, 2010 (level of evidence 4C)
Asoh et al.11 published a retrospective study of 14 
patients with dysfunctional conduits in the RV outflow 
tract, of whom ten had mixed lesions, two had pulmo-
nary stenosis, and two had pulmonary insufficiency. The 
parameters of the echocardiography performed within 
the first 24 hours also showed decrease in RV pressure 
(82.2 ± 15.6 mmHg to 61 ± 10 mmHg; P < 0.01) and 
in the RV outflow tract gradient (59.6 ± 26.8 mmHg 
to 41 ± 19.1 mmHg; P < 0.05). The hemodynamic im-
provement of these three studies is described in Table 2.
Three studies published in 2011 were retrieved.15,16,21
Biernacka, 2011 (level of evidence 4C)
Biernacka et al.21 presented data on 22 patients 
submitted to TPVI at the European Congress. There 
were nine patients with pure pulmonary stenosis, 11 
with mixed dysfunction, and two with pure pulmonary 
insufficiency. The procedural success rate was 96%. 
They observed improvement in NYHA functional class 
six months after the procedure, which remained stable 
at 12 months and24 months (P <  0.005). There was a 
significant improvement in the mean pulmonary in-
sufficiency fraction one month after the TPVI (15.7 ± 
11.1%to 2.6 ± 2.9%; P  =  0.0005).
Eicken, 2011 (level of evidence 4C)
Eicken et al.16 reported data on 102 patients, of 
which 36 had pulmonary stenosis, 18 had pulmonary 
insufficiency and 48 had mixed lesion. Pulmonary 
insufficiency, assessed by nuclear magnetic resonance 
(NMR), was significantly reduced (P < 0.001). RV-end 
diastolic volume was also evaluated by NMR and de-
creased from 106 mL/m² (93-133 mL/m²) to90 mL/m² 
(71-108 mL/m², P < 0.001).
Kenny, 2011 (level of evidence 4C)
Kenny et al.15 published the only study using a 
valve different than Melody, the SAPIEN Pulmonic 
THV (Edwards, Irvine, California, United States), which 
included 34 patients. The implantation success rate was 
97.1%. There was improvement in hemodynamics, as 
observed with the Melody valve (Table 2). After the 
procedure, pulmonary insufficiency was classified as 
minimal in 31 of 33 implantation procedures.
Two studies were published in 2013.14 ,22
Gillespie, 2013 (level of evidence 4C)
Gillespie et al.22 presented a series of 104 cases 
from eight centers in the United States submitted to 
TPVI with Melody valve. There were hemodynamic 
benefits, described in Table 2, with no morbidities or 
deaths related to the procedure. After 12 months of 
follow-up, no patient had mild pulmonary insufficiency 
and only four patients had a gradient > 30 mmHg in 
the RV outflow tract.
Butera, 2013 (level of evidence 3B)
A prospective, multicenter study published by Butera 
et al.14 reported an experience in 63 patients undergo-
ing TPVI. The success rate of the procedure was 97%. 
In 51 patients with pulmonary stenosis (21with pure 
pulmonary stenosis and 30 with associated pulmonary 
insufficiency), RV pressure and RV outflow tract gradient 
decreased significantly (Table 2). In the 42 patients with 
severe pulmonary insufficiency (12 with pure pulmo-
nary insufficiency and 30 with associated pulmonary 
stenosis), the degree of pulmonary insufficiency also 
decreased (pre-TPVI: 42 patients with grade ≥ 2; post-
TPVI: four patients).
Immediate hemodynamic results
According to the NYHA criteria, there was statis-
tically significant improvement in functional class in 
most studies (class II to I). The same occurred with 
hemodynamics parameters. A significant decrease in 
RV systolic pressure and reduction in the RV outflow 
tract gradient were observed in 100 % of the analysed 
studies (Table 2).
Few studies4,13,17,18 reported data on systolic pul-
monary artery pressure. For this parameter, only two 
studies13,17 showed a significant increase of 26 mmHg 
to 30  mmHg.
Regarding diastolic blood pressure in the pulmonary 
artery,sevenstudies4,8,12,13,19 reported this outcome; there 
was significant pressure increase in all of them (Table 2).
Safety
The main complications are described in Table 3. 
In general, the immediate mortality rate related to TPVI 
was < 1%. The rate of endocarditis was small and often 
associated with dental procedure without prophylaxis at 
the late follow-up.4,8,16 In many studies,4,20 when stent 
fracture occurred during follow-up, TPVI was performed 
again without complications.
Recommendations from medical specialties and 
regulatory entities
ANVISA approved the use of the transcatheter pul-
monary valve (Melody) for the treatment of patients 
with the following clinical conditions:
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• Patients with prosthetic conduits in the RV out-
flow tract, with pulmonary insufficiency and clinical 
indication for invasive or surgical intervention;
• Patients with prosthetic conduits in the RV outflow 
tract with pulmonary stenosis and in whom the risk of 
regurgitation worsening is a relative contraindication to 
balloon dilation or stent implantation;
• existence of a complete conduit (circumferential) 
in the RV outflow tract, whose original diameter was 
≥ 16 mm and < 22 mm when implanted.
The FDA and specialty societies in cardiology in 
Europe (European Society of Cardiology [ESC], European 
Association for Cardio-Thoracic Surgery [EACTS],and 
National Institute for Clinical Excellence [NICE]) also 
approve the performance of TPVI for patients with pul-
monary insufficiency and pulmonary stenosis.23-26 It is 
important to remember that the study that culminated 
with the approval of Melody valve by the FDA through 
HDE was a continuation of the first trial published by 
Zahn et al.19 In this second study with over150 patients, 
recently published by McElhinney et al.,27 the risks of 
procedures requiring immediate surgical intervention 
were very low (<1%) and included coronary artery 
compression by the valve, conduit rupture, or stent 
migration. Initially observed hemodynamics benefits 
were maintained during follow-up, with most patients 
in functional class I or II, non-significant gradients in 
the RV outflow tract, and adequate valve function dur-
ing a three-year period. Stent fractures were observed 
in 25% of cases, in a mean follow-up of 12 months, 
and 38% of these patients needed to have a second 
device implanted.
The American Heart Association (AHA) recently pub-
lished a document to define guidelines for percutaneous 
procedures in congenital heart defects, in which they 
recommend TPVI as class II A – level of evidence B.28
Recommendations for percutaneous implantation 
of pulmonary valve, adapted from the American 
Heart Association recommendations
Class IIa
Percutaneous implantation of pulmonary valve is 
indicated in patients weighing > 20-30 kg in the post-
operative period of surgeries during which conduits were 
used to restore the continuity of the right ventricle to 
the pulmonary artery, and that have objective evidence 
of conduit dysfunction (significant stenosis and/or re-
gurgitation) and meet the pre-established inclusion and 
exclusion criteria (level of evidence: B).
The SBHCI is at the final stages of preparing its 
guidelines for percutaneous treatment of congenital 
heart diseases, which is in agreement with the posi-
tion adopted by the AHA (Carlos A. C. Stone, personal 
communication).
FINAL CONSIDERATIONS
Dysfunctions in the RV outflow tract, especially 
pulmonary insufficiency when associated with pulmonary 
stenosis, is associated with undesirable hemodynamic 
effects in the long term, such as RV dilation and dys-
function, tricuspid valve regurgitation, arrhythmias, and 
death.1-3 The conduits used in the surgical correction 
of RV outflow tract dysfunctions frequently develop 
regurgitation and/or progressive stenosis requiring 
multiple surgeries, which result in significant mobility 
and mortality in these patients.1-3 The Melody valve 
prosthesis, developed by Bonhoeffer et al.7 to be per-
cutaneously implanted, brought considerable benefits 
to patients with dysfunctions in the RV outflow tract, 
as it simultaneously corrects pulmonary insufficiency 
and stenosis. A significant decrease in RV systolic 
pressure can be observed when using this valved 
device, due to stenosis relief in its outflow tract, also 
determining are duction or abolition of pulmonary 
reflow in those cases with predominant regurgita-
tion. The hemodynamic improvement observed after 
TPVI and during the late follow-up of these patients 
was also confirmed by echocardiography assessment 
and magnetic resonance imaging, directly related to 
reduction in the RV intracavitary pressure and of the 
systolic gradient in its outflow tract and in the pul-
monary regurgitation rate. 
From a clinical standpoint, TPVI is also associated 
with improved functional capacity of patients. The ana-
lysed studies demonstrated that, after the implantation, 
most of the patients developed mild symptoms or even 
no symptoms, little or no limitation of routine activities, 
and comfortat rest. This reflects a significant improvement 
in quality of life of this population. TPVI also showed 
immediate mortality < 1%, significant periprocedural 
morbidity < 4%, and medium-term survival of 96.6%. 
Thus, the procedure was shown to be safe, providing 
an increase in years of survival for the patients.
It is important to recall that TPVI is a high-
complexity procedure and should be performed by 
surgeons acquainted with the percutaneous treatment 
of congenital heart disease, particularly the implant of 
stents in conduits and pulmonary arteries. It requires 
a variety of materials for its performance and possible 
treatment of complications (e.g. coated stent implan-
tation in the conduit in case of ruptured conduit). 
Specific training to allow the surgeon to perform this 
type of procedure is necessary before its large-scale 
use. In this sense, SBHCI has led this initiative: the 
training guidelines have already been established and 
consolidated for percutaneous aortic valve implanta-
tion in the elderly.
Finally, the aim of this article was to address more 
specifically the use of the Melody valve, according to 
its on-label use in conduits between the right ventricle 
and the pulmonary artery. There are numerous cases 
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of off-label use for treatment of native outflow tracts, 
where there is a clear anchor point for the device (John 
Cheatham, personal communication).The Melody valve 
has been used in the tricuspid, mitral, and aortic positions 
with optimal initial published results.29,30 Such specific 
uses must be considered in patients and institutions in 
an individualized and personalized manner.
CONCLUSIONS
TPVI is a safe and effective procedure in the treat-
ment of dysfunctions (pulmonary stenosis, pulmonary 
regurgitation, or both) of homografts, bioprosthesis, and 
other valved conduits surgically implanted in the RV 
outflow. Such functional recovery is achieved without the 
need for CPB, and is associated with great immediate 
and medium-term outcomes. Although there have been 
no studies comparing the percutaneous and the surgical 
techniques, current evidence in the literature suggests 
that TPVI should be the first-choice procedure or, at 
least, an excellent therapeutic alternative for patients 
with dysfunctions in the conduits of RV outflow tract.
CONFLICTS OF INTEREST
Evidências company was hired and provided services 
to Medtronic to perform this systematic review. Carlos 
A. C. Pedra is a lecturer at Medtronic. The remaining 
authors declare to have no conflicts of interests.
REFERENCES
 1. Hoffman JIE. Valves and conduits. In: Hoffman JIE, editor. The 
natural and unatural history of congenital heart disease. New 
York: Blackwell; 2009. p. 37-56.
 2. d’Udekem Y, Rubay J, Ovaert C. Failure of right ventricular 
recovery of fallot patients after pulmonary valve replacement: 
delay of reoperation or surgical technique? J Am Coll Cardiol. 
2001;37(7):2008-9.
 3. Therrien J, Siu SC, McLaughlin PR, Liu PP, Williams WG, 
Webb GD. Pulmonary valve replacement in adults late after 
repair of tetralogy of fallot: are we operating too late? J Am 
Coll Cardiol. 2000;36(5):1670-5.
 4. Lurz P, Coats L, Khambadkone S, Nordmeyer J, Boudjemline Y, 
Schievano S, et al. Percutaneous pulmonary valve implantation: 
impact of evolving technology and learning curve on clinical 
outcome. Circulation. 2008;117(15):1964-72.
 5. Pedra CA, Justino H, Nykanen DG, Van Arsdell G, Coles JG, 
Williams WG, et al. Percutaneous stent implantation to ste-
notic bioprosthetic valves in the pulmonary position. J Thorac 
Cardiovasc Surg. 2002;124(1):82-7.
 6. Rossi Filho RI, Manica JLL, Borges MS, Machado PRM. Im-
plante de stent não-valvado na via de saída do ventrículo 
direito: forma simples e efetiva de retardar nova intervenção 
cirúrgica. Rev Bras Cardiol Invasiva. 2009;17(1):102-9.
 7. Bonhoeffer P, Boudjemline Y, Saliba Z, Hausse AO, Aggoun 
Y, Bonnet D, et al. Transcatheter implantation of a bovine 
valve in pulmonary position: a lamb study. Circulation. 2000; 
102(7):813-6.
 8. Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick G, 
Tsang V, et al. Percutaneous pulmonary valve implantation 
in humans: results in 59 consecutive patients. Circulation. 
2005;112(8):1189-97.
 9. Martins JD, Ewert P, Sousa L, Freitas I, Trigo C, Jalles N, et al. 
Percutaneous pulmonary valve implantation: initial experience. 
Rev Port Cardiol. 2010;29(12):1839-46.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, 
Ioannidis JP, et al. The PRISMA statement for reporting sys-
tematic reviews and meta-analyses of studies that evaluate 
health care interventions: explanation and elaboration. Ann 
Intern Med. 2009;151(4):W65-94.
11. Asoh K, Walsh M, Hickey E, Nagiub M, Chaturvedi R, Lee KJ, 
et al. Percutaneous pulmonary valve implantation within bio-
prosthetic valves. Eur Heart J. 2010;31(11):1404-9.
12. Momenah TS, El Oakley R, Al Najashi K, Khoshhal S, Al 
Qethamy H, Bonhoeffer P. Extended application of percutane-
ous pulmonary valve implantation. J Am Coll Cardiol. 2009; 
53(20):1859-63.
13. Vezmar M, Chaturvedi R, Lee KJ, Almeida C, Manlhiot C, 
McCrindle BW, et al. Percutaneous pulmonary valve implanta-
tion in the young 2- year follo-w up. JACC Cardiovasc Interv. 
2010;3(4):439-48.
ANNEX 
Levels of scientific evidence according to the classification of the Oxford Centre for Evidence-Based Medicine
Grade of recommendation Level of Evidence Study Treatment
A 1A Systematic review of randomized controlled trials
1B Randomized controlled trial with narrow confidence interval
1C Therapeutic results of “all or nothing”
B 2A Systematic review of cohort studies
2B Cohort study (including low-quality randomized clinical trial)
2C Observation of therapeutic results (outcomes research); ecological study
3A Systematic review of case-control studies
3B Case-control
C 4 Case report (including cohort or case-control lower quality)
D 5 Opinion devoid of criticism or review based on raw materials 
(physiological studies or animal studies)
Botrel et al. 
Transcatheter Implantation of Bioprosthesis Pulmonary Valvular
Rev Bras Cardiol Invasiva. 
2013;21(2):176-87
187
14. Butera G, Milanesi O, Spadoni I, Piazza L, Donti A, Ricci 
C, et al. Melody transcatheter pulmonary valve implantation. 
Results from the registry of the Italian society of pediatric 
cardiology. Catheter Cardiovasc Interv. 2013;81(2):310- 6.
15. Kenny D, Hijazi ZM, Kar S, Rhodes J, Mullen M, Makkar 
R, et al. Percutaneous implantation of the Edwards SAPIEN 
transcatheter heart valve for conduit failure in the pulmonary 
position: early phase 1 results from an international multicenter 
clinical trial. J Am Coll Cardiol. 2011;58(21):2248-56.
16. Eicken A, Ewert P, Hager A, Peters B, Fratz S, Kuehne T, et al. 
Percutaneous pulmonary valve implantation: two- centre experience 
with more than 100 patients. Eur Heart J. 2011; 32(10):1260 -5.
17. Coats L, Khambadkone S, Derrick G, Sridharan S, Schievano S, 
Mist B, et al. Physiological and clinical consequences of relief 
of right ventricular outflow tract obstruction late after repair of 
congenital heart defects. Circulation. 2006;113(17): 2037- 44.
18. Coats L, Khambadkone S, Derrick G, Hughes M, Jones R, Mist 
B, et al. Physiological consequences of percutaneous pulmo-
nary valve implantation: the different behaviour of volume -and 
pressure overloaded ventricles. Eur Heart J. 2007;28(15):1886-93.
19. Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implanta-
tion of the melody transcatheter pulmonary valve in patients 
with a dysfunctional right ventricular outflow tract conduit 
early results from the U.S. Clinical trial. J Am Coll Cardiol. 
2009;54(18):1722-9.
20. Nordmeyer J, Lurz P, Tsang VT, Coats L, Walker F, Taylor AM, 
et al. Effective transcatheter valve implantation after pulmonary 
homograft failure: a new perspective on the Ross operation. 
J Thorac Cardiovasc Surg. 2009;138(1):84-8.
21. Biernacka EK, Demkow M, Spiewak M, Kowalski M, Misko 
J, Hoffman P, et al. Transcatheter pulmonary valve implanta-
tion – results in 22 patients [Internet]. Warsaw: Institute of 
Cardiology; 2011 [cited 2013 May 15]. Available from: http://
spo.escardio.org/eslides/view.aspx?eevtid=48&fp=P5755 
22. Gillespie MJ, Rome JJ, Levi DS, Williams RJ, Rhodes JF, Cheatham 
JP, et al. Melody valve implant within failed bioprosthetic 
valves in the pulmonary position: a multicenter experience. 
Circ Cardiovasc Interv. 2012;5(6):862-70. 
23. U.S. Food and Drug Administration. Medtronic Melody Trans-
catheter Pulmonary Valve (TPV) and Ensemble Transcatheter 
Valve Delivery System H080002 [Internet]. Silver Spring; 2012 




24. European Association for Cardio -Thoracic Surgery (EACTS) 
[Internet]. Windsor; 2012 [cited 2012cDec13]. Available from: 
http://www.eacts.org
25. European Society of Cardiology (ESC) [Internet]. 2012 [cited 
2012 Dec 13]. Available from: www.escardio.org
26. National Institute for Health and Care Excellence (NICE) [In-
ternet]. London; 2012 [cited 2012 Dec 13]. Available from: 
www.nice.org.uk/
27. McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, 
Cheatham JP, Lock JE, et al. Short and medium -term outcomes 
after transcatheter pulmonary valve placement in the expanded 
multicenter US Melody valve trial. Circulation. 2010;122(5): 
507- 16.
28. Feltes TF, Bacha E, Beekman RH 3rd, Cheatham JP, Feinstein 
JA, Gomes AS, et al. Indications for cardiac catheterization 
and intervention in pediatric cardiac disease: a scientific 
statement from the American Heart Association. Circulation. 
2011;123(22):2307-52. 
29. Roberts PA, Boudjemline Y, Cheatham JP, Eicken A, Ewert P, 
McElhinney DB, et al. Percutaneous tricuspid valve replacement 
in congenital and acquired heart disease. J Am Coll Cardiol. 
2011;58(2):117-22.
30. Hasan BS, McElhinney DB, Brown DW, Cheatham JP, Vincent 
JA, Hellenbrand WE, et al. Short term performance of the 
transcatheter Melody valve in high -pressure hemodynamic 
environments in the pulmonary and systemic circulations. 
Circ Cardiovasc Interv. 2011;4(6):615-20.
